Nektar Therapeutics

NCM: NKTR

Live Quote

📈 ZcoreAI Score

Our AI model analyzes Nektar Therapeutics's price action across multiple timeframes using regression channels and statistical scoring.

Get NKTR Z-Score →

About Nektar Therapeutics

Healthcare Biotechnology

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

📊 Fundamental Analysis

Nektar Therapeutics demonstrates a profit margin of -297.1%, which is below the sector average, suggesting competitive pressure.

The company recently reported -25.3% revenue growth, which is negative, indicating a recent decline in revenue.

Return on Equity (ROE) is -217.9%, which indicates that capital utilization is currently under pressure.

At a current price of $77.50, NKTR currently trades near the top of its 52-week range (98%) (Range: $7.99 - $78.95).

🏥 Financial Health

🔴 Profit Margin Weak

🔴 Debt/Equity Elevated

🔴 Revenue Growth Weak

🔴 Return on Equity Weak

⚠️ Beta (Risk) Moderate Volatility

Key Financials

Market Cap

$2.22B

Trailing P/E

Forward P/E

-6.90

Beta (5Y)

1.18

52W High

$78.95

52W Low

$7.99

Avg Volume

1.11M

Day High

Day Low

Get NKTR Z-Score on Dashboard 🚀